Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Yee Chung Cheng MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Froedtert East Clinics
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
06/1983 - 03/1988 BS, University of Santo Tomas, Manila, Philippines
06/1988 - 04/1992 MD, University of Santo Tomas, Manila, Philippines

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
05/1992 - 04/1993 Rotating Internship, Santo Tomas University Hospital, Manila, Philippines
07/1995 - 06/1996 Internship, Internal Medicine, Beth Israel Medical Center, New York, NY
07/1996 - 06/1998 Residency, Internal Medicine, Beth Israel Medical Center, New York, NY
07/1998 - 06/1999 Fellowship, Medicine, Hematology and Oncology, North Shore University Hospital, Manhasset, NY
07/1999 - 06/2001 Fellowship, Medicine, Hematology and Oncology, Baylor College of Medicine Affiliated Hospital, Houston, TX
07/2001 - 06/2002 Clinical Fellowship, Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
07/2002 - 06/2003 Research Fellowship, Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

FACULTY APPOINTMENTS:
07/2003 - 10/2003 Research Assistant, Medicine and Therapeutics, Haematology, Chinese University of Hong Kong, Shatin, Hong Kong
01/2004 - 04/2011 Assistant Professor, Medicine, Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI
04/2011 - Present Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
07/2006 - Present Associate Program Director, Hematology and Oncology Fellowship Program, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
02/2006 - 06/2014 Chief, Medicine, Hematology and Oncology, Clement J. Zablocki VA Medical Center, Milwaukee, WI
09/2012 - 01/2020 Chairman, Cancer Committee, Medicine, Hematology and Oncology, Clement J. Zablocki VA Medical Center, Milwaukee, WI
06/2018 - 06/2021 Chief, Medicine, Hematology and Oncology, Clement J. Zablocki VA Medical Center, Milwaukee, WI
09/2021 - 01/2022 Deputy Chief, Medicine, Hematology and Oncology, Clement J. Zablocki VA Medical Center, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
01/2004 - Present Clement J. Zablocki VA Medical Center, 5000 W. National Avenue, Milwaukee, WI 53295-1000
03/2004 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., WI 53226
06/2011 - Present Community Memorial Hospital, W180N8085 Town Hall Road, Menomonee Falls, WI 53051
09/2011 - Present The Alyce and Elmore Kraemer Cancer Care Center and St. Joseph’s Hospital, 1110 Oak Street, West Bend, WI 53095

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Internal Medicine
08/2000
08/2010
Medical Oncology
11/2002
11/2032
Hematology
11/2005
11/2015
   
Certificates
Issued By Issue DateExpiration
BLS
AHA
09/2020
09/2024
    

Licensure
Number Issue DateExpiration
Wisconsin License
45354
02/19/2003
10/31/2025
DEA
BC8264347
10/01/2003
08/31/2026
    

AWARDS AND HONORS:
02/2004 Travel Grant Award, Oral Abstract Presentation, Annual Meeting of the American Society for Blood and Marrow Transplantation, Orlando, Florida
06/2007 Finalist in Best Teaching Faculty at the VA Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
05/2008 The Dennis M. Bush Excellence in Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
06/2008 Finalist in Best Teaching Faculty at the VA Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
06/2009 Finalist in Best Teaching Faculty at the VA Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
06/2010 Finalist in Best Teaching Faculty at the VA Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
03/2011 Best Doctors in America 2011
06/2011 Finalist in Best Teaching Faculty at the VA Teaching Award, Medical College of Wisconsin, Department of Medicine, Milwaukee, WI
09/2012 Best Doctors in America 2012
08/2013 Best Doctors in America 2013
09/2014 Best Doctors in America 2014
09/2015 Best Doctors in America 2015
08/2016 Best Doctors in America 2016
07/2017 Best Doctors in America 2017
07/2018 Best Doctors in America 2018
07/2019 Best Doctors in America 2019
07/2020 Best Doctors in America 2020
07/2021 Best Doctors in America 2021
01/2022 Best Doctors in America 2022
01/2023 Best Doctors in America 2023
01/2024 Best Doctors in America 2024

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
07/1995 - 06/1998 American College of Physician
07/1998 - Present American Society of Hematology
07/1998 - Present American Society of Clinical Oncology
07/2001 - 06/2003 American Society of Blood and Marrow Transplantation
07/2001 - Present The University of Texas MD Anderson Alumni & Faculty Association
07/2004 - Present Association of VA Hematology/Oncology
07/2005 - 06/2006 The International Nodal Ratio Working Group
02/2012 - Present Medical College of Wisconsin Cancer Center
05/2017 - Present Hoosier Cancer Research Network - Breast Clinical Trial Working Group
04/2018 - Present Alliance for Clinical Trials in Oncology - Breast Committee
11/2019 - Present The University of Texas MD Anderson Cancer Center Inflammatory Breast Cancer Connect

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
British Medical Journal
Clinical Breast Cancer
Journal of Cancer

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
11/2019 - Present Team Leader, MCW IBC team, University of Texas MD Anderson Cancer Center Inflammatory Breast Cancer Connect

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Non-Peer Review
Title:
ALLIANCE A012103: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy
Source:
Alliance for Clinical Trials in Oncology
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
  
Title:
SEAGEN-SGNTUC-028-HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Source:
Seagen
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
  
Title:
HCRN BRE18-334: Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer
Source:
Hoosier Cancer Research Network
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
  
Pending
Peer Review
Title:
Novel DNA Cross-Linking Agents and Combination Strategies for Tumor-Specific Activation
Source:
University of Wisconsin in Milwaukee/NIH R15 Grant Application
Role & Effort:
Co-Investigator
  
Title:
UIC Protocol 2020-1644: Potassium Channels as Therapeutic Targets in Triple-Negative Breast Cancer
Source:
University of Illinois in Chicago/DOD
Role & Effort:
Co-Investigator
  
Prior
Non-Peer Review
Title:
In-House: A Phase II Study of Neoadjuvant Chemotherapy with Epirubicin, Cyclophosphamide and Taxotere in Locally Advanced Breast Cancer
Source:
Medical College of Wisconsin, Milwaukee, Wisconsin
Role & Effort:
Principle Investigator
PI:
Yee Chung Cheng
Dates:
10/20/2003 - 05/27/2008
  
Title:
OPTIMIZE2: A Prospective, Randomized, Double-Blind, Stratified, Placebo-Controlled, Multi-Center, 3-Arm Trial of the Continued Efficacy and Safety of Zometa® (Every 4 weeks vs. Every 12 weeks vs. Placebo) in Patients with Documented Bone Metastases from Breast Cancer
Source:
Novartis Pharmaceuticals
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
06/11/2006 - 11/25/2013
  
Title:
B9E-US-S377: A Randomized Phase II Trial of Paclitaxel and Bevacizumab versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
Source:
Eli Lilly
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
08/21/2006 - 11/25/2009
  
Title:
B9E-US-S377: A Randomized Phase II Trial of Paclitaxel and Bevacizumab versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer
Source:
Eli Lilly
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
08/21/2006 - 11/25/2009
  
Title:
NKV102549: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Source:
GlaxoSmithKline
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
02/26/2007 - 06/21/2007
  
Title:
VEG108838: A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing, Relapsed or Refractory Inflammatory Breast Cancer
Source:
GlaxoSmithKline
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
05/28/2008 - 11/11/2008
  
Title:
BOLERO-2: A Randomized, Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to Letrozole or Anastrozole
Source:
Novartis Pharmaceuticals
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
06/23/2010 - 03/10/2011
  
Title:
ECOG 2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Source:
Eastern Cooperative Oncology Group
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
11/22/2011 - 07/23/2015
  
Title:
NSABP B47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Source:
National Surgical Adjuvant Breast and Bowel Project
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
07/09/2013 - 02/10/2015
  
Title:
SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Source:
Southwest Oncology Group
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
04/02/2014 - 05/01/2019
  
Title:
ALLIANCE A221301: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo Controlled Trial
Source:
Alliance for Clinical Trials in Oncology
Role & Effort:
Local Principal Investigator
PI:
Yee Chung Cheng
Dates:
03/02/2015 - 03/16/2016
  
Title:
ALLIANCE A011203: A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic Estrogen Receptor Positive, Her2 Negative Breast Cancer
Source:
Alliance for Clinical Trials in Oncology
Role & Effort:
Alliance for Clinical Trials in Oncology
PI:
Yee Chung Cheng
Dates:
07/08/2016 - 04/17/2017
  
Title:
WON UW16112: A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide In Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Source:
Wisconsin Oncology Network/MCW Cancer Center
Role & Effort:
Study Chairman
Dates:
02/21/2018 - 03/20/2020
Direct Funds:
$150,000
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
National
Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT, Low Prevalence of Premature Ovarian Failure (POF) in Women who Received Reduced-Intensity Conditioning (RIC) Regimens for Hematopoietic Stem-Cell Transplantation (HST), Poster Presentation/Discussion in the 39th Annual Meeting of the American Society of Clinical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 05/2003
Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT, Reduced-Intensity Conditioning (RIC) Regimens Result in Low Prevalence of Premature Ovarian Failure (POF) in Women Underwent Hematopoietic Stem-Cell Transplantation (HST)., Oral Presentation in the 2004 Annual Meeting of the American Society for Blood and Marrow Transplantation, Orlando, Florida, The University of Texas MD Anderson Cancer Center, Houston, Texas, 02/2004
Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT, Phase II Study of Gonadotropin-Releasing Hormone Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients., Poster Presentation/Discussion in the 46th Annual Meeting of the American Society of Clinical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 05/2010
Cheng YC, Liu Z, Huls MH, Gee AP, Heslop HE, Rooney CM, Experience with Real Time PCR Quantitation of EBV DNA to Monitor Patients at High Risk of EBV-Lymphoproliferative Disease., Oral Presentation in the 7th Annual Meeting of the International Society for Hematotherapy and Graft Engineering, Baylor College of Medicine, Houston, Texas, 06/2021
Cheng YC, Current Controversies in Adjuvant Therapy., Inflammatory Breast Cancer Connect Webinar Lecture, MD Anderson Cancer Center, 11/11/2021
Cheng YC, Follow Up Post-Trimodal Treatment: How to Personalize Based on the Risk of Recurrence, 7th International Inflammatory Breast Cancer Symposium: Understanding and Managing Aggressive Breast Cancer, Houston, Texas, 12/04/2022
 
Regional
Cheng YC, Breast Cancer Update 2011, Speaker in the Community Oncology Seminar Series, Racine, Wisconsin, 10/18/2011
Cheng YC, Triple Negative Breast Cancer Update in 2017, Speaker in the Green Bay Oncology Lecture, St. Vincent Hospital, Green Bay, Wisconsin, 06/16/2017
 
Local
Cheng YC, Update of Breast Cancer Screening., Speaker in the Grand Round, Department of Medicine, Clement J. Zablocki Veteran Affairs Medical Center, Milwaukee, Wisconsin, 01/23/2009 - 10/23/2009
Cheng YC, Breast Cancer Case Discussion, Panelist in the Medical College of Wisconsin Melodie Wilson Oldenburg Breast Cancer Symposium, Milwaukee, Wisconsin, 10/03/2014
Cheng YC, Triple Negative Breast Cancer, Speaker in the First Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/30/2016
Cheng YC, Triple Negative Breast Cancer, Speaker in the Second Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/28/2017
Cheng YC, Co-Chair and Moderator, Third Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/27/2018
Cheng YC, Breast Cancer Case Discussion, Panelist in the First Annual Cancer Disparities Symposium: A Focus on the Burden of Triple-Negative Breast Cancer, Milwaukee, Wisconsin, 09/08/2018
Cheng YC, Hormone Receptor Positive Metastatic Breast Cancer, Speaker in the Fourth Annual Susan G. Komen Wisconsin Metastatic Breast Cancer Conference, Milwaukee, Wisconsin, 05/01/2019
Cheng YC, Locally Advanced HER2+ Breast Cancer, Speaker in the OncLive State of the Science Summit: Breast Cancer, Milwaukee, Wisconsin, 05/21/2019
Cheng YC, Triple Negative Breast Cancer, Speaker in the Fifth Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/25/2020
Cheng YC, Triple Negative Breast Cancer, Speaker in the Sixth Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/23/2021
Cheng YC, Triple Negative Breast Cancer and Others, Speaker in the Eighth Annual Wisconsin Review of the San Antonio Breast Cancer Symposium, Milwaukee, Wisconsin, 01/28/2023
Cheng YC, Antibody-Drug Conjugates in HER2- Breast Cancer, Speaker in the OncLive State of the Science Summit: Breast Cancer, Milwaukee, Wisconsin, 09/06/2023
 

COMMITTEE SERVICE:
Hospital
10/2021 - Present Member, Breast Disease-Oriented Team, Froedtert Cancer Center
10/2023 - Present Member, Scientific Review Committee, Froedtert Cancer Center
 

MCW TEACHING ACTIVITIES:
Resident and Fellow Education
2006 - 2010 Breast Cancer in Internal Medicine didactic lecture
2008 - Present riple Negative Breast Cancer in Fellowship didactic lecture
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
2018 - 2022 Nithya Sridhar, Research mentor, Medical College of Wisconsin
2019 - 2023 Hefei Liu, Research mentor, Medical College of Wisconsin
2022 - Present Amber Bo, Research mentor, Medical College of Wisconsin
 
Clinical/Research Fellows
2004 - 2005 Magdalena Flejsierowicz, Research/clinical mentor, Medical College of Wisconsin
2005 - 2008 Mohamed Ahmed, Research/clinical mentor, Medical College of Wisconsin
2006 - 2009 Xin Yao, Research/clinical mentor, Medical College of Wisconsin
2008 - 2011 Veerpal Singh, Research/clinical mentor, Medical College of Wisconsin
2015 - 2018 Zeeshan Jawa, Research/clinical mentor, Medical College of Wisconsin
2019 - 2022 Edward McKenna, Research/clinical mentor, Medical College of Wisconsin
2022 Bicky Thapa, Research mentor, Medical College of Wisconsin
 
Residents
2007 Mahazarin Kaikobad, Research mentor, Medical College of Wisconsin
2010 - 2011 Sumna Devata, Research Mentor, Medical College of Wisconsin
2018 Chad Glisch, Research Mentor, Medical College of Wisconsin
2022 Rachel Goodman, Research Mentor, Medical College of Wisconsin
2022 - 2023 Ruchi Patel, Research Mentor, Medical College of Wisconsin
2022 Adam Kidwell, Research Mentor, Medical College of Wisconsin
 
Faculty
2013 - 2018 Carlos Arce-Lara, Career mentor, Medical College of Wisconsin
2022 - Present Anannya Patwari, Research mentor, Medical College of Wisconsin
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Kaikobad M, Cheng YC, Choi H, Teves D. Primary mediastinal embryonal carcinoma masquerading as chronic pancreatitis. WMJ. 2007 Jul;106(4):225-8.
2. Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. Leuk Res. 2008 Sep;32(9):1476-9.
3. Flejsierowicz M, Ahmed MS, Kotov P, Cheng YC. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. WMJ. 2008 Jul;107(4):191-4.
4. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant. 2009 Jul;44(2):81-7.
5. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol. 2009 Dec;90(5):627-634.
6. Singh V, Devata S, Cheng YC. Carboplatin and docetaxel-induced acute pancreatitis: brief report. Int J Clin Oncol. 2010 Dec;15(6):642-4.
7. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2012 Jul;19(3):191-9. PMCID: PMC3860359
8. Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC. A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. J Cancer. 2012;3:145-51. PMCID: PMC3319980
9. Dong L, Yuan Y, Opansky C, Chen Y, Aguilera-Barrantes I, Wu S, Yuan R, Cao Q, Cheng YC, Sahoo D, Silverstein RL, Ren B. Diet-induced obesity links to ER positive breast cancer progression via LPA/PKD-1-CD36 signaling-mediated microvascular remodeling. Oncotarget. 2017 Apr 04;8(14):22550-22562. PMCID: PMC5410244
10. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer. 2017;8(6):1009-1017. PMCID: PMC5436253
11. Chaudhary LN, Jawa Z, Hanif A, Szabo A, Kamaraju S, Cheng YC, Chitambar CR. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ? WMJ. 2018 Jun;117(2):62-67.
12. Pierro M, Zurko J, Szabo A, Cheng YC, Kamaraju S, Burfeind J, Retseck J, Chitambar CR, Chaudhary LN. Matched Case Control Analysis of Breast Cancer- Specific Factors Affecting Risk of Developing SARS-CoV-2 Infection. WMJ. 2023 Dec;122(5):418-421.
13. Chaudhary LN, Jorns JM, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong AL, Patten C, Yen T, Cortina CS, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy. Breast Cancer Res Treat. 2023 Oct;201(3):387-396. PMCID: PMC10795510
14. Chaudhary LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy. Res Sq. 2023 Apr 07. PMCID: PMC10104267
15. Thapa B, Arobelidze S, Clark BA, Xuefei J, Daw H, Cheng YC, Patel M, Spiro TP, Haddad A. Metaplastic Breast Cancer: Characteristics and Survival Outcomes. Cureus. 2022 Aug;14(8):e28551. PMCID: PMC9517584
16. Brown SA, Sparapani R, Osinski K, Zhang J, Blessing J, Cheng F, Hamid A, Berman G, Lee K, BagheriMohamadiPour M, Lal JC, Kothari AN, Caraballo P, Noseworthy P, Johnson RH, Hansen K, Sun LY, Crotty B, Cheng YC, Olson J, Cardio-Oncology Artificial Intelligence Informatics & Precision (CAIP) Research Team Investigators. Establishing an interdisciplinary research team for cardio-oncology artificial intelligence informatics precision and health equity. Am Heart J Plus. 2022 Jan;13. PMCID: PMC9012235
17. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep;189(2):455-461.
18. Kamaraju S, Fowler AM, Weil E, Wisinski KB, Truong TH, Lehr M, Chaudhary LN, Cheng YC, Chitambar CR, Rui H, Yee D, Lange C. Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. Endocrinology. 2021 Aug 01;162(8).
19. Cheng YC, Ueno NT. Non-myeloablative Allogeneic Peripheral Blood Progenitor Cell Transplantation for Metastatic Breast Cancer and Metastatic Renal Cell Carcinoma: The MD Anderson Cancer Center Experience. Haematologica 87 (supplement number 6): 6-9, June 2002.
20. Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin RE, Khouri I. Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma after Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab. Leukemia and Lymphoma 44 (5): 829-832, May 2003.
21. Cheng YC, Ueno NT. Allogeneic Hematopoietic Stem-Cell Transplantation for Solid Tumors in the United States: A Review. Nippon Rinsho (Japanese Journal of Clinical Medicine) 61 (9): 1619-1634, Sept 2003.
22. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, IF Khouri, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid Induction of Complete Donor Chimerism by the Use of a Reduced-Intensity Conditioning Regimen Composed of Fludarabine and Melphalan in Allogeneic Stem Cell Transplantation for Metastatic Breast Cancer and Renal Cell Carcinoma. Blood 102 (10): 3829-3836, November 15, 2003.
23. Wagner H-J, Cheng YC, Huls H, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus Pre-emptive Intervention for EBV-Lymphoproliferative Disease. Blood 103 (10): 3979-3981, May 15, 2004.
24. Ueno NT, Cheng YC, Shpall EJ, Champlin RE. Autologous Hematopoeitic Stem Cell Transplantation in Breast Cancer: New Hope. Breast Diseases: A Year Book® Quarterly 15 (2): 113-117, July-September 2004.
25. Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The Use of High-Dose Cyclophosphamide, Carmustine, and Thiotepa plus Autologous Hematopoietic Stem-Cell Transplantation as Consolidation Therapy for High-Risk Primary Breast Cancer after Primary Surgery or Neoadjuvant Chemotherapy. Biology of Blood and Marrow Transplantation 10 (11): 794-804, November 2004.
26. Cheng YC, Tannir N, Champlin RE, Ueno NT. Allogeneic Hematopoietic Stem-Cell Transplantation for Metastatic Renal Cell Carcinoma. Kidney Cancer Journal 3 (3): 11-20, Autumn 2005.
27. Cheng YC, Saliba RM, Rondón G, Sergio GA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low Prevalence of Premature Ovarian Failure in Women Given Reduced-Intensity Conditioning Regimens for Hematopoietic Stem-Cell Transplantation. Haematologica 90 (12): 1725-1726, December 2005.
28. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology 24 (18): 2910-2916, June 20, 2006.
29. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural History of Metastatic Renal Cell Carcinoma in Patients who Undewent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 13 (8): 975-985, August 2007.
30. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic Hematopoietic Cell Transplantation for Metastatic Breast Cancer. Bone Marrow Transplantation 41 (6): 537-545, March 2008.
31. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of Granulocyte-Macrophage–Colony Stimulating Factor to Trastuzumab Stabilizes Diseases in Patients with Trastuzumab-Resistant, HER2-Positive Metastatic Breast Cancer. British Journal of Cancer 103 (9): 1331-1334, October 26, 2010.
32. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II Study of Gonadotropin-Releasing Hormone Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. The Oncologist 17 (2): 233-238, Jan 26, 2012.
33. Cheng YC, Rondón G, Anderlini P, Khouri IF, Richard E. Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer 4 (8): 679-685, Sept 27, 2013.
34. Sridhar N, Glisch C, Jawa Z, Chaudhary LN, Kamaraju S, Burfeind J, Charlson J, Chitambar CR, Jorns JM, Cheng YC. Androgen Receptor Expression in Patients with Triple Negative Breast Cancer treated with Neoadjuvant Chemotherapy: A Single Institution Study. Journal of Cancer 13(8):2472-2476, May 9, 2022.
35. Ueno NT, Cheng YC. Review of Conventional Adjuvant Chemotherapy With or Without High-Dose Chemotherapy and Autologous Stem Cell Transplantation in High-Risk Breast Cancer. The American Journal of Oncology Review 3 (1): 26-28, January 2004.
36. Ueno NT, Cheng YC. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. Breast Diseases: A Year Book® Quarterly 15 (1): 76, April-June 2004.
37. Ueno NT, Cheng YC. The Role of Transplantation in Metastatic Breast Cancer. M. D. Anderson Breast Medical Oncology: Clinical Issues & Therapeutic Advances 3 (1): 4-5, January 2004.
38. Cheng YC. Preliminary Investigation on Mutagenicity of Polar Components in the Bark Extracts of Alstonia scholaris and Nauclea junghuhuii by Ames Test. Bachelor of Science Thesis, Advisor: Rosalinda Solevilla, Ph.D., University of Santo Tomas, Manila, Philippines, March 1988.
 
Books, Chapters, and Reviews
1. Cheng YC, Ueno NT. High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation in Inflammatory Breast Cancer. In: Ueno NT, Cristofanilli M, editors. Inflammatory Breast Cancer: An Update, 1st edition. Springer. Chapter 12: 127-138, 2012.
 
Editorials, Letters To Editor, Other
1. Ueno NT, Cheng YC. The Future of Allogeneic Hematopoietic Stem-Cell Transplantation for Metastatic Renal Cell Carcinoma in the Era of Target Specific Therapy. Bone Marrow Transplantation 38 (11): 711-714, December 2006.
2. Cheng YC, Ueno NT. Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal? Women’s Health 6 (4): 481-485, July 2010.
 
Abstracts
1. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist. 2012;17(2):233-8. PMCID: PMC3286172
2. Sridhar N, Glisch C, Jawa Z, Chaudhary LN, Kamaraju S, Burfeind J, Charlson J, Chitambar CR, Jorns JM, Cheng YC. Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution study. J Cancer. 2022;13(8):2472-2476. PMCID: PMC9174868
3. Cheng YC, Liu Z, Huls MH, Gee AP, Heslop HE, Rooney CM. Experience with Real Time PCR Quantitation of EBV DNA to Monitor Patients at High Risk of EBV-Lymphoproliferative Disease. Baylor College of Medicine, Houston, Texas. Oral Presentation and Abstract #124 in the 7th Annual Meeting of the International Society for Hematotherapy and Graft Engineering, Quebec City, Canada, June 2001.
4. Wagner H-J, Cheng YC, Liu Z, Savoldo B, Huls MH, Gee AP, Heslop HE, Rooney CM. Monitoring of Transplanted Patients at Risk of Epstein-Barr Virus-Induced Lymphoproliferative Disorder by Real Time PCR Quantification of EBV DNA in Peripheral Blood. Baylor College of Medicine, Houston, Texas. Oral Presentation and Abstract #2004 in the 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, December 2001.
5. Ueno NT, Cheng YC, Giralt SA, Rondón G, Gajewski JL, Tannir NM, Pagliaro LC, Hortobagyi GN, Champlin RE. Complete Donor Chimerism by Fludarabine/ Melphalan in Mini-allogeneic Transplantation for Metastatic Renal Cell Carcinoma and Breast Cancer. The University of Texas MD Anderson Cancer Center, Houston, Texas. Oral Presentation and Abstract #1659 in the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 2002.
6. Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low Prevalence of Premature Ovarian Failure (POF) in Women who Received Reduced-Intensity Conditioning (RIC) Regimens for Hematopoietic Stem-Cell Transplantation (HST). The University of Texas MD Anderson Cancer Center, Houston, Texas. Poster Presentation/Discussion and Abstract # 3350 in the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 2003.
7. Ueno NT, Rizzo JD, Hegenbart U, Cheng YC, Rondón G, Antman K, Stiff PJ, Demirer T, Horowitz MM, Niederwieser D, IBMTR and EBMT Solid Tumor Working Committees. International Bone Marrow Transplant Registry/The European Group for Blood and Marrow Transplantation (IBMTR/EBMT) Review of Allogeneic Hematopoietic Stem-Cell Transplantation (Allo HSCT) in Metastatic Breast Cancer (MBC). International Bone Marrow Transplant Registry (IBMTR)/Autologous Blood and Marrow Transplant Registry (ABMTR); The European Group for Blood and Marrow Transplantation (EBMT); Medical College of Wisconsin, Milwaukee, Wisconsin. Oral Presentation and Abstract # 3345 in the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 2003.
8. Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Reduced-Intensity Conditioning (RIC) Regimens Result in Low Prevalence of Premature Ovarian Failure (POF) in Women Underwent Hematopoietic Stem-Cell Transplantation (HST). The University of Texas MD Anderson Cancer Center, Houston, Texas. Oral Presentation and Abstract #51 in the 2004 Annual Meeting of the American Society for Blood and Marrow Transplantation, Orlando, Florida, February 2004.
9. Cheng YC, Rondón G, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Gajewski JL, Champlin RE, Ueno NT. Interleukin-2 (IL-2) With High-Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem-Cell Transplantation (AHST) for Poor-Risk Metastatic Breast Cancer (MBC). The University of Texas MD Anderson Cancer Center, Houston, Texas. Poster Presentation and Abstract #4234 in the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
10. Ueno NT, Rizzo JD, Cheng YC, Childs R, Stiff PJ, Demirer T, Horowitz MM, Niederwieser D. Allogeneic Hematopoietic Cell Transplantation (Allo HCT) for Metastatic Breast Cancer (MBC). The University of Texas MD Anderson Cancer Center, Houston, Texas; Center for International Blood and Marrow Transplant Research (CIBMTR); The European Group for Blood and Marrow Transplantation (EBMT); Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Presentation and Abstract #82 in the 2006 Annual Meeting of the American Society for Blood and Marrow Transplantation, Honolulu, Hawaii, February 2006.
11. Cheng YC, Valero V, Davis ML, Hortobagyi GN, Ueno NT. Addition of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to Trastuzumab Stabilizes Disease in Patients with Trastuzumab-Resistant, HER2+ Metastatic Breast Cancer. Medical College of Wisconsin, Milwaukee, Wisconsin; The University of Texas MD Anderson Cancer Center, Houston, Texas. Poster Presentation and Abstract #5103 in the 32nd Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2009.
12. Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC. Phase II Study of Combined Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer in a Single Institution. Medical College of Wisconsin, Milwaukee, Wisconsin. Abstract #11040 in the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 2010.
13. Giever TA, Adwan KM, Cheng YC, Atallah E. Statin Decrease the Incidence of Venous Thromboembolism (VTE) in Patients with Cancer. Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin. Poster Presentation/Discussion and Abstract #9033 in the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 2010.
14. Devata S, Cheng YC, Pfeifer Kurt. An Unexpected Presentation of Breast Cancer. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Presentation and Abstract in the 34th Annual Meeting of the Society of General Internal Medicine, Phoenix, Arizona, May 2011.
15. Huang J, Chitambar CR, Behmaram B, Cheng YC, Basir Z, Walker A. The Unique Role of ER-α36 in Maintaining a Close Relationship between ER-α66 and HER2 in Breast Cancer. Medical College of Wisconsin, Milwaukee, Wisconsin. Modern Pathology 2013, Volume 26, Supplement 2: 46A. Abstract in the 102nd Annual Meeting of the United States and Canadian Academy of Pathology, Baltimore, Maryland, March 2013.
16. Pattali S, Harding N, Visotcky A, Basir Z, Charlson JA, Cheng YC, Banerjee A, Chitambar CR. Value of Mitotic Index in Residual Tumors following Neoadjuvant Therapy for Breast Cancer: Single Institution Experience. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Presentation and Abstract #548 in the 52nd Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 2016.
17. Cheng YC, Smith E, Yen T. Overall Survival of Patients with Non-Metastatic Triple Negative Breast Cancer Who Received Neoadjuvant vs Adjuvant Chemotherapy: Cohort Analysis of National Cancer Data Base (NCDB) 2010 – 2011. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Presentation and Abstract # 1289 in the 39th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2016.
18. Jawa ZA, Glisch C, Badar T, Chaudhary L, Kamaraju S, Burfeind JD, Charlson JA, Chitambar CR, Aguilera-Barrantes I, Jorns J, Lagunova V, Cheng YC. Morbid Obesity is Related with Adverse Outcomes in Triple Negative Breast Cancer; a Single Institution Study. Medical College of Wisconsin, Milwaukee, Wisconsin. Abstract # e12663 in the 54th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 2018.
19. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Raghavendra1 A, Sinha A, Espinosa Fernandez JR, James A, Yamagishi K, Matsushima T, Tripathy D, Tada S, Jackson RS, Martino L, Waite K, Noguchi S, Nakanmura S, Acoba J, and Ueno NT. A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence risk in patients with estrogen receptor-positive, node-negative, early-stage primary invasive breast cancer with intermediate recurrence score according to Oncotype Dx. The University of Texas MD Anderson Cancer Center, Houston, Texas. Poster Presentation and Abstract # in the 55th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 2019.
20. Chaudhary LN, Jorns JM, Cheng YC, Kamaraju S, Gonyo MB, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Banarjee A, Wang Y, Chitambar CR, Rui H. Neoadjuvant endocrine therapy helps identify HER2 up-regulation in patients with hormone receptor-positive HER2-negative breast cancer. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Discussion and Abstract # 934 in the 43rd Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2020.
21. Cheng YC, O’Regan R, Chaudhary Lubna, Kamaraju S, Einhorn H, Sampene E, Pigsley M, Burkard ME, Chitambar CR, Wisinski KB. A phase II study of neoadjuvant weekly carboplatin/paclitaxel followed by dose-dense doxorubicin/cyclophosphamide (DD AC) in patients with triple negative breast cancer (TNBC): Wisconsin Oncology Network (WON) study. Medical College of Wisconsin, Milwaukee, Wisconsin. Poster Presentation and Abstract # 1771 in the 43rd Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2020.
22. Zurko J, Szabo A, Cheng YC, Kamaraju S, Burfeind J, Retseck J, Chitambar CR, Chaudhary LN. Matched case control analysis of breast cancer specific factors impacting risk of developing SARS-Cov-2 infection. Abstract # e18579 in the 57th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 2021.
23. Kamaraju S, Fowler A, Cheng YC, Chaudhary LN, Burfeind J, Retseck J, Tevaarwerk AJ, Burkard M, Paplomata E, Parkes AM, Jorns JM, Tarima S, Yee D, Rui H, Lange C, Sahmoud T, Wisinski KB. The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. Poster Presentation and Abstract # OT2-16-01 in the 44th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2021.
24. Chaudhary LN, Jorns JM, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Banerjee A, Wang Y, Sun Y, Chitambar CR, Rui H. HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer. Poster Presentation and Abstract # P4-02-03 in the 44th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2021.
25. Goodman R, Thordsen S, Sriidhar N, Calderon A, Weil E, Chaudhary L, Kamaraju S, Retseck J, Charlson J, Burfeind J, Chitambar C, Cheng YC, Brown SA. Change in left ventricular end diastolic index or global longitudinal strain may predict development of cancer therapy related cardiac dysfunction in HER2 positive breast cancer patients receiving trastuzumab. Poster presentation and Abstract 12422 in the 71st Annual Scientific Session of the American College of Cardiology, Washington, D.C., April 2022.
26. Chaudhary LN, Chervoneva I, Peck AR, Sun YG, Yi MS, Langenheim JF, Jorns JM, Kamaraju S, Cheng YC, Burfeind J, Chitambar CR, Hooke JA, Kovstich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Pestell RG, Mitchell EP, Rui H. High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors. Poster Presentation and Abstract # P2-11-13 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
27. Monahan K, Kamaraju S, Cheng YC, Retseck J, Sriram D, Burfeind J, Chitambar CR, Chaudhary LN. Real World Statistics on CDK 4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2 Negative Breast Cancer with a Focus on Age. Poster Presentation and Abstract # P4-01-19 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
28. Min H, Weil E, Nelson M, Charlson J, Conroy M, Powell M, Cheng YC, Chaudhary LN, Burfeind J, Retseck J, Sriram D, Kamaraju S. Improving Health-Related Quality of Life with Outpatient High-Dose Methotrexate Regimen Among Solid Tumor Oncology Patients with Intracranial Metastases: a Qualitative Study. Poster Presentation and Abstract # P5-07-05 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
29. Cotchett KR, Kelly AH, Szabo A, Chitambar CR, Kamaraju S, Cheng YC, Burfeind J, Charlson J, Wallace L, Chaudhary LN. Depression and Psychological Distress in Breast Cancer. Poster Presentation and Abstract # P6-05-34 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
30. Conroy M, Powell M, Nagavally S, Dawson AZ, Beckius A, Sweeney M, Min H, Weil E, Halbach A, Cheng YC, Chaudhary LN, Wright T, Charlson J, Kamaraju S. Addressing Healthcare Gaps and Disparities in EMR Messages: a Quality Improvement Project Among Breast Cancer Patients. Poster Presentation and Abstract # P6-05-52 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
31. Kamaraju S, Fowler A, Chaudhary LN, Burkard M, Giever T, Cheng YC, Parkes A, Jorns JM, Retseck J, Sriram D, Lange C, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Zurbriggen L, Rui H, Wisinski KB. The SMILE study: A phase II trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. Poster Presentation and Abstract # OT2-01-02 in the 45th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2022.
32. Patel R, Weil E, Carroll E, Burfeind J, Chaudhary LN, Deininger J, Halbach A, Kamaraju S, Mooney C, Retseck J, Sriram D, Sweeney M, Cheng YC. Evaluation and Management of Incomplete Ovarian Function Suppression in Premenopausal Breast Cancer Patients Receiving Anti-Hormone Therapy. Poster Presentation and Abstract in the 19th Annual Conference of the Hematology/Oncology Pharmacy Association, Phoenix, Arizona, March 2023.
33. Chaudhary LN, Jorns JM, Sun YG, Kamaraju S, Cheng YC, Kong A, Yen T, Patten C, Cortina C, Chervoneva I, Chitambar CR, Rui H. Frequent Discordance in PD-L1 and PD-L2 Protein Expression in Breast Cancer. Poster Presentation and Abstract in the Annual Congress of the European Society for Medical Oncology Breast Cancer, Berlin, Germany, May 2023.
34. Harris A, Szabl A, Kamaraju S, Cheng YC, Burfeind J, Chitambar CR, Chaudhary LN. Impact of Neighborhood Disadvantage on Stage at Diagnosis and Five-Year Recurrence Rates in Women Diagnosed with Breast Cancer. Accepted for online publication in the 59th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 2023.
35. Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM. Use of Pathology Reports via Online Portals in Patients with Breast, Gastrointestinal, Genitourinary, and Thoracic Malignancies. Accepted for Poster Presentation and Abstract in the 2023 National Conference of the College of American Pathologists, Chicago, Illinois, October 2023.
36. Chaudhary LN, Jorns JM, Sun YG, Kamaraju S, Cheng YC, Kong A, Yen T, Patten C, Cortina C, Chervoneva I, Chitambar CR, Rui H. PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer. Poster Presentation and Abstract # P03-13-05 in the 46th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2023.
37. Iwase T, Nithya S, Kai M, Willey J, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross HTC, Nasrazadani A, Saleem S, Layman R, Valero V, Tripaathy D, Woodward W, Cheng YC, Nakhlis F, Bellon J, Lynce F, Ueno N. Neoadjuvant HER2-targeted Regimens with or without Anthracyclines for HER2-positive Inflammatory Breast Cancer (IBC): a Multicenter Retrospective Study. Poster Presentation and Abstract # P05-01-03 in the 46th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2023.